CNN
–
The manufacturer said on Monday that the experimental therapy, Cantineromab, failed to help people at risk of memory loss from Alzheimer’s disease or those who were in the early stages of the disease.
GANTERUMAB is part of a category of injected drugs designed to remove sticky protein pieces called beta -amyloid from the brain. Beta Amyloid Buildup is a distinctive feature of Alzheimer’s disease.
Most of these medications have worked as aiming to wipe the beta amyloid, but many of them still have failed to show any realistic benefits for patients; Brain and memory functions do not improve significantly, despite treatment.
Roche said on Monday that Gantennerumab seems to have removed less than Amelid Beta from the brains of the study participants, which was expected. The company said that the results of the third stage of its experiments, called graduates, were difficult but important to participate.
“Many of our families have been directly affected by Bazheimer’s, so this news is very disappointing,” said Dr. Levy Garway, the chief medical official in Roche and the head of global products development. press release. “Although the results of graduate studies are not what we were hoping, we are proud to hand over the high and comprehensive Alzheimer’s data collection to this field, and we look forward to this complex disease.”
Roche said she would share more results from her studies at a coming medical conference.
GANTEREREREMAMAAB results follow the positive results of the various drugs that reduce beta -amyloid, lecanemab. The companies that test this medicine, biujin and EISAI have announced this year that Lecaneemab has slowed down the decrease in the function of the brain in Alzheimer’s disease by about 27 % compared to the imaginary medicine. Some experts feel that a degree of benefit is equal to the controversial degree in the drug ADUHELM, which has been approved by American food and medicine, despite the lack of support from independent advisors of the agency.
Dr. Constantine Likitsus, professor of psychiatry at Johns Hopkins College of Medicine, said that if Gantrinderum is removed as much as the company predicted in beta, it has shown a degree of benefit to be in line with Likanimab and Adhm.
“In other words, it is a very modest but not clinical effect,” said Licksos, who did not participate in the research.
Al -Zheimer’s Association said in a statement that the results of the Roche study are “disappointing”, but it remains “optimistic about this category of treatment.”
“Every anti -amydid treatment that is tested works differently, and the research must continue to be effective and safe. Maria Carillo, chief scientific official in the statement, said it is important to evaluate each treatment independently.
About 6.5 million Americans live with Alzheimer’s disease in 2022, according to Alzheimer’s Association.